Pharmacogenomic application of the haptoglobin genotype in the treatment of HDL dysfunction

Area of Science:

• Biochemistry
• Cardiology
• Pharmacogenomics

Background:

• Diabetes mellitus (DM) is associated with increased cardiovascular disease (CVD) risk, partly due to altered high-density lipoprotein (HDL) function.
• Oxidative modification of HDL impairs its cholesterol efflux, antioxidant, and anti-inflammatory properties, contributing to atherosclerosis in DM.
• Previous antioxidant strategies have failed to reduce cardiovascular events in DM, possibly due to poor patient selection.

Purpose of the Study:

• To review evidence suggesting haptoglobin (Hp) genotype can identify diabetic individuals with oxidatively modified HDL.
• To explore the potential of vitamin E as a targeted antioxidant therapy for this specific patient subset.
• To propose a pharmacogenomic approach for optimizing antioxidant therapy in DM patients.

Main Methods:

• Review of existing research on HDL modification in diabetes.
• Analysis of studies investigating the role of haptoglobin (Hp) in HDL function.
• Evaluation of antioxidant therapy outcomes in relation to Hp genotype.

Main Results:

• Evidence suggests that haptoglobin (Hp) can identify individuals with functionally impaired HDL in diabetes mellitus.
• Vitamin E therapy may be effective in improving HDL function and providing cardioprotection in Hp-defined subsets of DM patients.
• The failure of broad antioxidant strategies may be linked to the lack of Hp-based patient stratification.

Conclusions:

• Haptoglobin (Hp) genotype is a potential biomarker for identifying diabetic patients who will benefit from antioxidant therapy.
• Targeted antioxidant interventions, such as vitamin E, guided by Hp genotype could improve cardiovascular outcomes in DM.
• A pharmacogenomic approach utilizing Hp genotype holds promise for personalized cardiovascular risk reduction in diabetes.